Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Paromomycin Sulfate

FDA-approved product (capsule, oral), marketed as Humatin, Paromomycin Sulfate.

Registered studies
36
Lab records
3
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Paromomycin Sulfate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Amebiasis
  • Infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antibiotics
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC A07AA06

Repurposing investigation

Paromomycin Sulfate is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA71.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli63.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae96.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis66.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

36registered studies name this medicine, for any condition. See them below.

Experimental

  • MRSA: measured active in 1 of 1 lab record
  • E. coli: measured active in 2 of 2 lab records
Open Paromomycin Sulfate in ChEMBL Registered studies below
Show the 3 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Paromomycin Sulfate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Efficacy of Topical Liposomal Form of Drugs in Cutaneous Leishmaniasis

    NCT01050777 · start 2011-03

    Registered record
    Registry ID
    NCT01050777
    Conditions
    Cutaneous Leishmaniasis
    Interventions
    Liposomal meglumine antimoniate (Glucantime); Liposomal meglumine antimoniate; Liposomal Paromomycin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2011-03
    Completion
    2012-03
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCutaneous Leishmaniasis
    InterventionLiposomal meglumine antimoniate (Glucantime); Liposomal meglumine antimoniate; Liposomal Paromomycin; Placebo
    PhaseEarly phase 1
    Registry statusCompleted

  • An Effectiveness Study of Paromomycin IM Injection (PMIM) for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh

    NCT01328457 · start 2011-01

    Registered record
    Registry ID
    NCT01328457
    Conditions
    Visceral Leishmaniasis
    Interventions
    Paromomycin sulfate
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2011-01
    Completion
    2012-06
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVisceral Leishmaniasis
    InterventionParomomycin sulfate
    PhaseNot applicable
    Registry statusCompleted

  • Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh

    NCT01122771 · start 2010-05

    Registered record
    Registry ID
    NCT01122771
    Conditions
    Visceral Leishmaniasis
    Interventions
    Liposomal amphotericin B; liposomal amphotericin B + miltefosine; liposomal amphotericin B + paromomycin; Miltefosine + Paromomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-05
    Completion
    2014-03
    Enrolment
    602

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVisceral Leishmaniasis
    InterventionLiposomal amphotericin B; liposomal amphotericin B + miltefosine; liposomal amphotericin B + paromomycin; Miltefosine + Paromomycin
    PhasePhase 3
    Registry statusCompleted

  • Pharmacokinetics, Safety, and Efficacy Trial of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream for the Treatment of Cutaneous Leishmaniasis in Panama

    NCT01083576 · start 2010-03

    Registered record
    Registry ID
    NCT01083576
    Conditions
    Leishmaniasis, Cutaneous
    Interventions
    WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream); Paromomycin Alone Cream (15% paromomycin topical cream)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-03
    Completion
    2011-07
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeishmaniasis, Cutaneous
    InterventionWR 279,396 (15% paromomycin + 0.5% gentamicin topical cream); Paromomycin Alone Cream (15% paromomycin topical cream)
    PhasePhase 2
    Registry statusCompleted

  • Safety, Efficacy and Pharmacokinetics (PK) Study of WR 279,396 Versus Paromomycin for Treatment of Cutaneous Leishmaniasis (Peru-PK)

    NCT01032382 · start 2010-01

    Registered record
    Registry ID
    NCT01032382
    Conditions
    Leishmaniasis, Cutaneous
    Interventions
    WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream); Paromomycin Alone Cream (15% paromomycin topical cream)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-01
    Completion
    2011-07
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeishmaniasis, Cutaneous
    InterventionWR 279,396 (15% paromomycin + 0.5% gentamicin topical cream); Paromomycin Alone Cream (15% paromomycin topical cream)
    PhasePhase 2
    Registry statusCompleted

  • Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral Leishmaniasis

    NCT00696969 · start 2008-06

    Registered record
    Registry ID
    NCT00696969
    Conditions
    Visceral Leishmaniasis
    Interventions
    Amphotericin B Deoxycholate; Ambisome + Miltefosine; Ambisome and Paromomycin; Miltefosine and Paromomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-06
    Completion
    2010-01
    Enrolment
    634

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVisceral Leishmaniasis
    InterventionAmphotericin B Deoxycholate; Ambisome + Miltefosine; Ambisome and Paromomycin; Miltefosine and Paromomycin
    PhasePhase 3
    Registry statusCompleted

  • An Open Lable Randomised Study to Assess the Safety and Efficacy of Short Course Paromomycin in Visceral Leishmaniasis

    NCT00629031 · start 2008-02

    Registered record
    Registry ID
    NCT00629031
    Conditions
    Visceral Leishmaniasis
    Interventions
    Paromomycin; Paromomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-02
    Completion
    2008-08
    Enrolment
    329

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVisceral Leishmaniasis
    InterventionParomomycin; Paromomycin
    PhasePhase 3
    Registry statusCompleted

  • Phase 3 Study to Evaluate WR 279,396 vs. Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia)

    NCT00606580 · start 2008-01

    Registered record
    Registry ID
    NCT00606580
    Conditions
    Cutaneous Leishmaniasis
    Interventions
    WR 279,396 topical cream; Paromomycin Alone topical cream; Vehicle placebo cream
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-01
    Completion
    2011-07
    Enrolment
    375

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCutaneous Leishmaniasis
    InterventionWR 279,396 topical cream; Paromomycin Alone topical cream; Vehicle placebo cream
    PhasePhase 3
    Registry statusCompleted

  • Expand Access/Assess Safety and Efficacy of Paromomycin IM Injection for the Treatment of Visceral Leishmaniasis

    NCT00604955 · start 2007-10

    Registered record
    Registry ID
    NCT00604955
    Conditions
    Visceral Leishmaniasis
    Interventions
    Paromomycin sulfate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-10
    Completion
    2010-01
    Enrolment
    2,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVisceral Leishmaniasis
    InterventionParomomycin sulfate
    PhasePhase 4
    Registry statusCompleted

  • Combination Therapy in Indian Visceral Leishmaniasis

    NCT00523965 · start 2007-09

    Registered record
    Registry ID
    NCT00523965
    Conditions
    Leishmaniasis, Visceral
    Interventions
    amphotericin B deoxycholate; Liposomal Amphotericin B with Miltefosine; Liposomal Amphotericin B and Paromomycin Sulfate; miltefosine + Paromomycin sulfate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-09
    Completion
    2010-02
    Enrolment
    624

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeishmaniasis, Visceral
    Interventionamphotericin B deoxycholate; Liposomal Amphotericin B with Miltefosine; Liposomal Amphotericin B and Paromomycin Sulfate; miltefosine + Paromomycin sulfate
    PhasePhase 3
    Registry statusCompleted

  • Cosmetic Outcome of Leishmaniasis Scar After WR279396 Application

    NCT00490230 · start 2007-04

    Registered record
    Registry ID
    NCT00490230
    Conditions
    Cutaneous Leishmaniasis; Scar
    Interventions
    WR 279396
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2007-04
    Completion
    2007-06
    Enrolment
    108

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCutaneous Leishmaniasis; Scar
    InterventionWR 279396
    PhaseNot applicable
    Registry statusCompleted

  • Topical Treatment of Recalcitrant Ulcerative Old World Leishmaniasis With WR 279,396

    NCT00657917 · start 2006-12-20

    Registered record
    Registry ID
    NCT00657917
    Conditions
    Cutaneous Leishmaniasis
    Interventions
    Paromomycin +Gentamicin topical cream
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2006-12-20
    Completion
    2010-06-24
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCutaneous Leishmaniasis
    InterventionParomomycin +Gentamicin topical cream
    PhasePhase 2
    Registry statusTerminated

  • A Study to Evaluate the Efficacy and Tolerance of WR279,396 for Old World Cutaneous Leishmaniasis

    NCT01536795 · start 2005-10

    Registered record
    Registry ID
    NCT01536795
    Conditions
    Old World Cutaneous Leishmaniasis
    Interventions
    WR279,396 with Tegaderm Dressing; WR 279,396 with Gauze and Tape Dressing
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-10
    Completion
    2007-02
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOld World Cutaneous Leishmaniasis
    InterventionWR279,396 with Tegaderm Dressing; WR 279,396 with Gauze and Tape Dressing
    PhasePhase 2
    Registry statusCompleted

  • Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V Leishmaniasis

    NCT00255567 · start 2004-11

    Registered record
    Registry ID
    NCT00255567
    Conditions
    Visceral Leishmaniasis
    Interventions
    Sodium Stibogluconate; Paromomycin sulphate; SSG and Paromomycin sulphate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-11
    Completion
    2010-01
    Enrolment
    1,142

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVisceral Leishmaniasis
    InterventionSodium Stibogluconate; Paromomycin sulphate; SSG and Paromomycin sulphate
    PhasePhase 3
    Registry statusCompleted

  • Safety and Efficacy Study of Paromomycin to Treat Visceral Leishmaniasis

    NCT00216346 · start 2003-06

    Registered record
    Registry ID
    NCT00216346
    Conditions
    Visceral Leishmaniasis
    Interventions
    Paromomycin sulfate; Amphotericin B
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-06
    Completion
    2004-11
    Enrolment
    667

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVisceral Leishmaniasis
    InterventionParomomycin sulfate; Amphotericin B
    PhasePhase 3
    Registry statusCompleted